Evidence map›Paper›PMID 40761602›Full record

ArticleImaging neuroscience (Cambridge, Mass.)2025

Spatial and Temporal Progression of Neurodegeneration in Confirmed and Suspected TDP-43 Type C Pathology.

Jane Stocks, Jordan Behn, Elena Barbieri, M-Marsel Mesulam

Abstract read
In one paragraph

Article in Imaging neuroscience (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Neuropathology-specific language features in primary progressive aphasia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Identifying neuropathologic disease in primary progressive aphasia using narrative speech.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jane StocksDepartment of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA 60611.
Jordan BehnMesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago IL, USA 60611.
Elena BarbieriMesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago IL, USA 60611.
M-Marsel MesulamMesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago IL, USA 60611.

Funding

Neuropathology CoreP30AG013854 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROGALSKI, EMILY J · 1996 to 2020
$28.9M
Research Education Core FP30AG072977 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SANDRA WEINTRAUB · 2021 to 2026
$26.3M
ASYMMETRIC NEURODEGENERATION AND LANGUAGE IN PRIMARY PROGRESSIVE APHASIAR01AG077444 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MAREK-MARSEL M MESULAM, EMILY J ROGALSKI · 2022 to 2026
$10.4M
Clinical, Neuroanatomic, and Pathologic Signatures of FTLD-tau in Dementia Phenotypes - Diversity Supplement (Antwan Howard)R01AG062566 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GEFEN, TAMAR D · 2020 to 2024
$2.1M
Anatomic, Pathologic, and Molecular Signatures of FTLD-TDP type CR01AG091388 · NIA · NORTHWESTERN UNIVERSITY · PI CHANGIZ GEULA, Tamar D Gefen · 2025 to 2026
$1.6M
NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG072977NIA NIH HHS R01 AG062566NIA NIH HHS R01 AG077444NIA NIH HHS R01 AG091388
6 · The paper itself

Abstract

The delineation of disease progression in neurodegenerative entities offers neurobiological insights into pathophysiology as well as practical information on natural progression that can be used to gauge the benefits of treatment. In AD, FTLD-tau and FTLD-TDP types A and B such advances have been achieved based on the investigation of presymptomatic mutation carriers. In the absence of dominant mutations, this approach is not feasible in FTLD-TDP type C (TDP-C). Considering the subtlety of the initial symptoms, it is almost certain that the disease had been progressing for years before the first investigations are obtained. We addressed this limitation through an indirect approach based on the fact that neurodegeneration in TDP-C can be asymmetric for 5-6 years after symptom onset. In time, the contralateral hemisphere starts to show the onset of atrophy, the spread of which mirrors the pattern in the affected hemisphere. The unaffected hemisphere therefore offers an opportunity for capturing the very first emergence of atrophy. To that end, we traced the onset and progression of neurodegeneration in TDP-C by analyzing the right hemisphere longitudinally in cases of asymmetric left anterior temporal atrophy. In these cases, TDP-C was either confirmed at autopsy or suspected based on the clinical features and anatomy of atrophy. Structural MRIs were processed using voxel-based morphometry and parcellated into cortical and subcortical regions. W-scores were computed to identify volume loss relative to age-matched controls. Linear mixed-effects models assessed disease progression across regions of interest (ROIs). Results of our analyses reveal that atrophy in TDP-C follows a stereotyped progression within the right hemisphere, beginning in the ventromedial anterior temporal lobe and extending posteriorly and laterally over time. Early atrophy was most prominent in the medial temporal pole (planum polare), perirhinal cortex, entorhinal cortex, and anterior fusiform cortex, with subcortical involvement initially limited to the amygdala. Voxelwise and ROI-based analyses confirmed that cortical atrophy preceded and exceeded amygdala atrophy in most cases, suggesting greater neocortical vulnerability. Longitudinal linear mixed-effects models identified the greatest volume loss in medial temporal ROIs and the amygdala, following a consistent anterior-to-posterior gradient over time. These findings reconstruct the spatial and temporal progression of TDP-C pathology using the initially unaffected hemisphere as a proxy for early disease stages. The stereotyped trajectory of atrophy aligns with neuropathological patterns and offers critical insights into disease progression, aiding therapeutic evaluation.

Indexed as

atrophylongitudinalMRINeurodegenerationprimary progressive aphasiaTDP-43

Identifiers

PMID40761602
PMCPMC12320738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.